JPWO2020247371A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247371A5 JPWO2020247371A5 JP2021571942A JP2021571942A JPWO2020247371A5 JP WO2020247371 A5 JPWO2020247371 A5 JP WO2020247371A5 JP 2021571942 A JP2021571942 A JP 2021571942A JP 2021571942 A JP2021571942 A JP 2021571942A JP WO2020247371 A5 JPWO2020247371 A5 JP WO2020247371A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- bone marrow
- syndrome
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107222A JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857169P | 2019-06-04 | 2019-06-04 | |
| US62/857,169 | 2019-06-04 | ||
| US201962867569P | 2019-06-27 | 2019-06-27 | |
| US62/867,569 | 2019-06-27 | ||
| US201962947948P | 2019-12-13 | 2019-12-13 | |
| US62/947,948 | 2019-12-13 | ||
| US202063032214P | 2020-05-29 | 2020-05-29 | |
| US63/032,214 | 2020-05-29 | ||
| PCT/US2020/035702 WO2020247371A1 (en) | 2019-06-04 | 2020-06-02 | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107222A Division JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535550A JP2022535550A (ja) | 2022-08-09 |
| JP2022535550A5 JP2022535550A5 (https=) | 2023-06-12 |
| JPWO2020247371A5 true JPWO2020247371A5 (https=) | 2023-06-12 |
| JP7716992B2 JP7716992B2 (ja) | 2025-08-01 |
Family
ID=73651973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571942A Active JP7716992B2 (ja) | 2019-06-04 | 2020-06-02 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
| JP2025107222A Pending JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107222A Pending JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12552873B2 (https=) |
| EP (1) | EP3980463A4 (https=) |
| JP (2) | JP7716992B2 (https=) |
| KR (1) | KR20220042055A (https=) |
| CN (1) | CN114401990A (https=) |
| AU (1) | AU2020288823A1 (https=) |
| BR (1) | BR112021024242A2 (https=) |
| CA (1) | CA3141334A1 (https=) |
| IL (1) | IL288510A (https=) |
| TW (1) | TW202110891A (https=) |
| WO (1) | WO2020247371A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| CA3141334A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| US20220284243A1 (en) * | 2021-03-03 | 2022-09-08 | International Business Machines Corporation | Ensemble voting classifiers using adjusted thresholds |
| WO2023091958A1 (en) * | 2021-11-17 | 2023-05-25 | Altrubio Inc. | Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| CN120682308B (zh) * | 2025-06-23 | 2025-12-02 | 北京昌盛鸿途生物科技有限公司 | 牛骨髓肽及其在提高免疫力中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852497B2 (en) | 2000-03-24 | 2005-02-08 | Genetics Institute, Llc | Methods of identifying compounds which inhibit binding of SLIC-1 to PSGL-1 |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| CN1897970A (zh) * | 2003-06-30 | 2007-01-17 | 生物技术通用（以色列）有限公司 | 特异人抗体 |
| CN1972703A (zh) | 2004-03-30 | 2007-05-30 | 丹麦皇家兽医和农业学院 | 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测 |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
| WO2009140623A2 (en) | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
| WO2011143411A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
| US20120130603A1 (en) | 2010-11-18 | 2012-05-24 | Sean Michael Simpson | System and method for controlling a transmission of a human-powered vehicle |
| WO2012088265A1 (en) * | 2010-12-21 | 2012-06-28 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| MX358447B (es) * | 2011-06-13 | 2018-08-21 | Abgenomics Cooeperatief U A Star | Anticuerpos anti-psgl-1 y usos de los mismos. |
| US9139652B2 (en) | 2011-10-21 | 2015-09-22 | Transgene Sa | Method for increasing M1 macrophages in a patient |
| WO2015077401A1 (en) | 2013-11-20 | 2015-05-28 | Drexel University | Compositions and methods for macrophage conversion |
| PT3166636T (pt) | 2014-07-08 | 2021-06-29 | Sanford Burnham Med Res Inst | Moduladores de psgl-1 e utilizações dos mesmos |
| US20170306042A1 (en) | 2014-08-29 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CN109789201B (zh) * | 2016-04-15 | 2023-06-16 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
| GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| EP3568159A4 (en) | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | PSGL-1 ANTAGONISTS AND THEIR USES |
| JP2021529753A (ja) | 2018-06-29 | 2021-11-04 | ヴェルソー セラピューティクス， インコーポレイテッド | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
| CA3141334A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
-
2020
- 2020-06-02 CA CA3141334A patent/CA3141334A1/en active Pending
- 2020-06-02 EP EP20818905.0A patent/EP3980463A4/en active Pending
- 2020-06-02 JP JP2021571942A patent/JP7716992B2/ja active Active
- 2020-06-02 TW TW109118529A patent/TW202110891A/zh unknown
- 2020-06-02 WO PCT/US2020/035702 patent/WO2020247371A1/en not_active Ceased
- 2020-06-02 CN CN202080055123.9A patent/CN114401990A/zh active Pending
- 2020-06-02 AU AU2020288823A patent/AU2020288823A1/en not_active Abandoned
- 2020-06-02 US US17/615,863 patent/US12552873B2/en active Active
- 2020-06-02 BR BR112021024242A patent/BR112021024242A2/pt unknown
- 2020-06-02 KR KR1020217040138A patent/KR20220042055A/ko active Pending
-
2021
- 2021-11-29 IL IL288510A patent/IL288510A/en unknown
-
2025
- 2025-06-25 JP JP2025107222A patent/JP2025129213A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12559718B2 (en) | Diagnostic methods for t cell therapy | |
| US9828435B2 (en) | Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency | |
| ES2961666T3 (es) | Métodos para determinar la dosificación de células CAR-T | |
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| US10983128B2 (en) | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy | |
| KR20180011250A (ko) | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 | |
| US12357646B2 (en) | Chimeric antigen receptor T cell therapy | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2024038034A (ja) | 膀胱癌の抗ｐｄ－ｌ１抗体治療 | |
| TW202238129A (zh) | Ｔ細胞療法 | |
| JPWO2020247371A5 (https=) | ||
| JPWO2020247372A5 (https=) | ||
| JPWO2020263651A5 (https=) | ||
| WO2021021991A1 (en) | Combined inhibition of semaphorin-4d and tgfb and compositions therefor | |
| JPWO2021243169A5 (https=) | ||
| JPWO2020263650A5 (https=) | ||
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| US20250290154A1 (en) | Predictive markers for immunotherapy | |
| CN120917153A (zh) | 肿瘤微环境对免疫疗法疗效的影响 |